Blood Reviews
Volume 22 , Pages S29-S34 , December 2008

The deleterious effects of iron overload in patients with myelodysplastic syndromes

  • François Dreyfus

      Affiliations

    • Corresponding Author InformationFrançois Dreyfus, MD. Service d'Hématologie, Hôopital Cochin, AP-HP, 27 rue du Faubourg Saint Jacques, Université Paris Descartes, 75014 Paris, France. Tel.: +33 (0)1 58 41 21 20; fax: +33 (0)1 58 41 19 95

References 

  1. Greenberg P , Cox C , LeBeau MM , et al.   International scoring system for evaluating prognosis in myelodysplastic syndromes . Blood . 1997;89:2079–2088
  2. Penninx BW , Guralnik JM , Onder G , et al.   Anemia and decline in physical performance among older persons . Am J Med . 2003;115:104–110
  3. Malcovati L , Porta MG , Pascutto C , et al.   Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making . J Clin Oncol . 2005;23:7594–7603
  4. Wu WC , Rathore SS , Wang Y , et al.   Blood transfusion in elderly patients with acute myocardial infarction . N Engl J Med . 2001;345:1230–1236
  5. Oliva EN , Dimitrov BD , Benedetto F , et al.   Haemoglobin level threshold for cardiac remodeling and quality of life in myelodysplastic syndrome . Leuk Res . 2005;29:1217–1219
  6. Cazzola M , Malcovati L . Myelodysplastic syndromes-coping with ineffective hematopoiesis . N Engl J Med . 2005;352:536–538
  7. Malcovati L , Della Porta MG , Cazzola M . Predicting survival and leukemic evolution in patients with myelodysplastic syndrome . Haematologica . 2006;91:1588–1590
  8. Nemeth E . Iron regulation and erythropoiesis . Curr Opin Hematol . 2008 May;15(3):169–175
  9. Winder A , Lefkowitz R , Ghoti H , et al.   Urinary hepcidin excretion in patients with myelodysplastic syndrome and myelofibrosis . Br J Haematol . 2008 Aug;142(4):669–671
  10. Brittenham GM , Olivieri NF , Roualt TA . In: Iron physiology and iron overload . American Society of Hematology, Education Programme; 1996;p. 177
  11. Grootveld M , Bell JD , Halliwell B , et al.   Non transferrin-bound iron in plasma or serum from patients with idiopathic haemochromatosis . J Biol Chem . 1989;264:4417–4422
  12. Breuer W , Greenberg E , Cabantchik ZI . Newly delivered transferrin iron and oxidative cell injury . FEBS Lett . 1997;403:213
  13. Cortelezzi A , Cattaneo C , Cristiani S , et al.   Nontransferrin-bound iron in myelodysplastic syndromes: a marker of ineffective erythropoiesis? . Hematol J . 2000;1:153–158
  14. Schafer AI , Cheron RG , Dluhy R , et al.   Clinical consequences of acquired transfusional iron overload in adults . N Engl J Med . 1981;304:319–324
  15. Buja LM , Roberts WC . Iron in the heart. Etiology and clinical significance . Am J Med . 1971;51:209–221
  16. Jaeger M , Aul C , Söhngen D , et al.   Sekundäre Hämochromatose bei polytransfundierten Patienten mit myelodysplastischen Syndromen . Beits Infusionsther . 1992;30:464–468
  17. Mathew P , Tefferi A , Dewald GW , et al.   The 5q-syndrome: a single-institution study of 43 consecutive patients . Blood . 1993;81:1040–1045
  18. Takatoku M , Uchiyama T , Okamoto S , et al.   Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anaemia highlights the negative impact of iron overload on morbidity/mortality . Eur J Haematol . 2007;78:487–494
  19. Goldberg SL , Mody-Patel N , Warnock N . Incidence of myelodysplastic syndromes in the United States Medicare population . Leuk Res . 2007;31(Suppl 1):S103; [abstract].
  20. Della Porta MG , Malcovati L , Travaglino E , et al.   A prognostic model for predicting the impact of comorbidities on survival of patients with myelodysplastic syndromes . Blood . 2007;110: abstract 2453.
  21. Deschler B , de Witte T , Mertelsham R , et al.   Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukaemia: problems and approaches . Haematologica . 2006;91:1513–1522
  22. Jensen PD , Jensen FT , Christensen T , et al.   Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool . Blood . 2003;101:4632–4639
  23. Chacko J , Pennell DJ , Tanner MA , et al.   Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions . Br J Haematol . 2007;138:587–593
  24. Konen E , Ghoti H , Goitein O , et al.   No evidence for myocardial iron overload in multitransfused patients with myelodysplastic syndrome using cardiac magnetic resonance T2* technique . Am J Hematol . 2007;82:1013–1016
  25. Anderson LJ , Holden S , Davis B , et al.   Cardiovascular T2- star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload . Eur Heart J . 2001;22:2171–2179
  26. Glanville J , Eleftheriou P , Porter JB . MRI evidence of cardiac iron accumulation in myelodysplasia and unusual anaemias [abstract] . Blood . 2006;108:1553
  27. Olivieri NF , Nathan DG , MacMillan JH , et al.   Survival in medically treated patients with homozygous beta-thalassemia . N Engl J Med . 1994;331:574–578
  28. Leitch HA . Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy . Leuk Res . 2007;31(Suppl 3):S7–S9
  29. Rose C , Brechignac S , Vassilief D , et al.   Positive impact of iron chelation therapy (CT) on survival in regularly transfused MDS patients. A prospective analysis by the GFM . Blood . 2007;110: abstract 249.
  30. Alessandrino EP , Amadori S , Barosi G , et al.   Evidence-and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology . Haematologica . 2002;87:1286–1306
  31. Bowen D , Culligan D , Jowitt S , et al.   Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes . Br J Haematol . 2003;120:187–200
  32. Gattermann N , Porter JB , Lopes LF , et al.   Consensus statement on iron overload in myelodysplastic syndromes . Hematol Oncol Clin North Am . 2005;19(Suppl 1):18–25
  33. National Comprehensive Cancer Network  . NCCN Clinical Practice Guidelines. Myelodysplastic Syndromes, v.2.2008 . www.nccn.org 2008;
  34. Gattermann N . Clinical consequences of iron overload in myelodysplastic syndromes and treatment with chelators . Hematol Oncol Clin North Am . 2005;19(Suppl 1):13–17

PII: S0268-960X(08)70006-7

doi: 10.1016/S0268-960X(08)70006-7

Blood Reviews
Volume 22 , Pages S29-S34 , December 2008

Article Tools